Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dubermatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 16/20 | 0.87 |
| ▸ | AURKA | O14965 | 1/20 | 0.87 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.87 |
| ▸ | NEK2 | P51955 | 1/20 | 0.69 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dubermatinib SCHEMBL29814405 | 1.00 | AXL (0.87) | AXLAURKAAURKBNEK2PTK2 | |
| Dubermatinib SCHEMBL30437663 | 1.00 | AXL (0.87) | AXLAURKAAURKBNEK2PTK2 | |
| Dubermatinib SCHEMBL12813478 | 0.93 | AXL (1.00) | AXLAURKAAURKBNEK2PTK2 | |
| Dubermatinib SCHEMBL29394359 | 0.93 | AXL (1.00) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL21446913 | 0.87 | AXL (0.87) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL24727537 | 0.86 | AXL (0.86) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL25550069 | 0.85 | AXL (0.84) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL25549741 | 0.85 | AXL (0.84) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL25838024 | 0.84 | AXL (0.83) | AXLAURKAAURKBNEK2PTK2 | |
| SCHEMBL25838086 | 0.84 | AXL (0.83) | AXLAURKAAURKBNEK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20220380348-A1 | AXL INHIBITOR FORMULATIONS | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11400091-B2 | AXL kinase inhibitors and use of the same | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11400091-B2 | AXL kinase inhibitors and use of the same | AXL, FLT3, TEC | AXL 1/4885AURKA 100/4885AURKB 167/4885 |
| US-20220380348-A1 | AXL INHIBITOR FORMULATIONS | AXL, FYN, SYK | AXL 1/4885AURKA 742/4885AURKB 1005/4885 |
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | AXL 1/4885AURKA 94/4885AURKB 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.